Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT05520814 |
| Other study ID # |
Ahead-NC-202207 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
Phase 2
|
| First received |
|
| Last updated |
|
| Start date |
August 1, 2018 |
| Est. completion date |
December 31, 2023 |
Study information
| Verified date |
September 2023 |
| Source |
Sichuan Cancer Hospital and Research Institute |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment
for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival
(PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already
confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and
radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1
inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainties
about the timing, fraction dose and total dose for PD-1 inhibitors combination with
radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new
pattern for R/M NPC.
Description:
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors of the head and
neck, which is derived from the epithelial cells of the nasopharynx. According to the
statistics of global cancer data in 2020, there are about 129100 newly diagnosed cases of
nasopharyngeal carcinoma (NPC) in the world every year, the incidence rate is less than 5 /
100000, and about 73000 people die from NPC every year. There are obvious ethnic and regional
differences in the incidence of nasopharyngeal carcinoma. From the global perspective, it is
more likely to occur in the yellow race, and southern China and Southeast Asia are high
incidence regions of nasopharyngeal carcinoma. According to statistics, the incidence rate of
nasopharyngeal carcinoma in southern China is as high as 30.29/100000 males and 13.09/100000
females. The incidence rate of male was higher than that of female. Because nasopharyngeal
carcinoma is sensitive to radiotherapy and chemotherapy, and because it is adjacent to the
spinal cord, brainstem, temporal lobe, optic nerve, cochlea, mandible and other important
tissue structures, it cannot be treated surgically. Therefore, radiotherapy (RT) or
radiotherapy combined with chemotherapy (chemotherapy) is the standard treatment for
nasopharyngeal carcinoma.
Although the diagnosis and treatment of nasopharyngeal carcinoma have been greatly improved
under the background of the development of imaging technology and the era of precision
radiotherapy, the situation it faces is still not optimistic. On the one hand, 4% - 10% of
newly diagnosed nasopharyngeal carcinoma has distant metastasis; on the other hand, about 10%
of nasopharyngeal carcinoma has local and regional recurrence after intensity modulated
radiation therapy (IMRT) ± chemotherapy, and 15% - 30% of patients have distant metastasis
after radical treatment. Therefore, recurrence and metastasis are still the main causes of
treatment failure of nasopharyngeal carcinoma. This poses a severe challenge to the treatment
mode of nasopharyngeal carcinoma (NPC).
In the era of traditional treatment, surgery is the first choice for the treatment of
recurrent nasopharyngeal carcinoma. The standard treatment for patients with recurrent or
metastatic nasopharyngeal carcinoma (R / M NPC) that cannot be cured by surgery is platinum
based dual drug palliative systemic chemotherapy. At present, the GP regimen of gemcitabine
combined with cisplatin is the standard first-line treatment for R / M NPC, but the
progression free survival (PFS) of first-line chemotherapy is still less than 7 months, and
the median overall survival (OS) is difficult to exceed 30 months [17]. In view of the
limited progress of chemotherapy drugs, we urgently need new treatment schemes to prolong the
survival time of R / M NPC patients. Immunotherapy is a hot topic in R / M NPC Research in
recent years, and it is expected to prolong the long-term survival of patients. Immunotherapy
also has a large number of clinical studies in R / M NPC patients, making the treatment of
nasopharyngeal carcinoma enter an era of immunotherapy.
The occurrence of nasopharyngeal carcinoma is related to the chronic infection of Epstein
Barr virus (EBV). Nasopharyngeal carcinoma cells infected with EBV express target proteins of
CD4 and CD8 positive T cells (CD4 + T and CD8 + T), and nasopharyngeal carcinoma cells
infected with EBV undergo four different latent cycles (phase 0-IV). The researchers found
that NPC cells expressed specific latent proteins (EBNA1, LMP1, LMP2 and lmp2b) in latent
phase II. Through basic research, it was found that these four latent proteins are EBV
antigens expressed by nasopharyngeal carcinoma cells, contain more CD4 + T and CD8 + T cell
epitopes, and are almost only expressed in nasopharyngeal carcinoma cells. Therefore, these
four latent proteins are ideal targets for immune precision therapy. On the other hand, there
are a large number of tumor infiltrating lymphocytes (TILs) in tumor tissues, including a
large number of CD4 + T and CD8 + T lymphocytes, which can accurately attack EBV antigens
expressed by nasopharyngeal carcinoma cells. However, in patients with nasopharyngeal
carcinoma with high lymphocyte infiltration, tumor cells can still continue to grow. This
phenomenon indicates that there is an immunosuppressive microenvironment in nasopharyngeal
carcinoma. Immunotherapy can effectively improve the immunosuppressive microenvironment,
making immunotherapy more widely used in the occurrence, development and clinical diagnosis
and treatment of nasopharyngeal carcinoma. Inhibitory receptors expressed by T cells,
antigen-presenting cells and other cells exert corresponding immune effects after binding
with their corresponding ligands, which are collectively referred to as "immune checkpoints".
Among them, programmed death receptor-1 (PD-1) and its ligand programmed death ligand-1
(PD-L1) are important targets of immunotherapy.
PD-L1 (also known as CD274 and B7-H1) is a type I transmembrane protein containing 290 amino
acids in the immunoglobulin superfamily, which is similar to the immunoglobulin light chain.
In 1999, it was found that it is expressed in the heart, placenta, lung and skeletal muscle
and regulates T cell proliferation. Through anti-T cell receptor and CD28 costimulatory
signal, it binds to its main receptor PD-1 in trans and CIS, thereby inhibiting the function
of anti-tumor PD-1 positive T cells. PD-L1 also interacts in cis and trans with another known
receptor, the immune co signaling molecule CD80, to prevent co stimulation of T cells. PD-1 /
PD-L1 pathway maintains the normal immune state of the body. In the tumor microenvironment,
PD-L1 expressed or overexpressed on the surface of tumor cells binds to the PD-1 target
expressed on the surface of T cells, inhibits the normal function of T cells, weakens the
recognition and response ability of T cells to tumor cells, thereby realizing tumor immune
escape and forming an immunosuppressive microenvironment. In short, the main anti-tumor
mechanism of PD-1 / PD-L1 inhibitors is to block PD-1 and its ligand PD-L1, which are
involved in attenuating the activation pathway of T cells, and prevent or reverse the
acquired peripheral tolerance to tumor antigens, thus leading to T cell recovery, reducing T
cell failure or death, increasing T cell memory and anti-tumor immune cell infiltration in
tumors, enhancing T cell activity, playing an anti-cancer role, and significantly prolonging
the survival of patients. Some researchers further found that PD-L1 overexpression was common
in NPC patients, which may be related to EBV infection. Comprehensive analysis shows that
there are a large number of immune cells in NPC tissues, but due to EBV infection and other
reasons, NPC cells overexpress PD-L1, resulting in immunosuppressive effect. The use of PD-1
immune checkpoint inhibitors can theoretically reactivate the immune response, so that
lymphocytes infiltrating the tumor microenvironment of nasopharyngeal carcinoma can play an
immune role, and ultimately achieve the goal of tumor suppression. Immunotherapy based on
PD-1 / PD-L1 immune checkpoint inhibitors has made a breakthrough in the treatment of
nasopharyngeal carcinoma. At present, many studies on anti-PD-1 monoclonal antibody in
nasopharyngeal carcinoma have been officially published.
Keynote-028 study is a non randomized, multicenter phase I and B clinical trial to explore
the efficacy and safety of pembrolizumab in patients with PD-L1 positive nasopharyngeal
carcinoma. Twenty seven NPC patients with PD-L1 expression who could not be operated or
distant metastasis and failed standard treatment were included in the study. The median
follow-up time was 20 months, the objective response rate (ORR) was 25.9%, the median PFS was
6.5 months, and the median OS was 16.5 months. PD-L1 expression had a certain correlation
with the treatment effect. The incidence of drug-related adverse events (AES) was 74.1%, and
the incidence of grade 3-5 AES was 29.6%. This study showed that pabilizumab showed strong
antitumor activity and manageable safety in pd-l1-positive recurrent / metastatic
nasopharyngeal carcinoma. Similar to pabolizumab, the nci-9742 study is a single arm,
multicenter phase II clinical study on nivolumab. 44 patients with nasopharyngeal carcinoma
who progressed after the treatment of advanced platinum containing regimen were enrolled in
the study, and received the single drug treatment regimen of nabulizumab. The final results
showed that 1 patient obtained Cr, 8 patients obtained pr (ORR 20.5%), the 1-year OS rate was
59%, and the tolerance was good. The results of the study confirmed that the monotherapy of
nabulizumab may be effective and safe for advanced nasopharyngeal carcinoma.
At present, PD-1 monoclonal antibody has shown a certain efficacy in patients with recurrent
/ metastatic nasopharyngeal carcinoma. The median PFS of immunomonotherapy used in the
posterior line treatment of R / M NPC is mostly 3-4 months, and the median OS is concentrated
in 16-17 months. The overall incidence of side effects is lower than that of chemotherapy,
and it is well tolerated. It can bring longer survival benefits for patients, but the benefit
population is small (20% - 30%).
In 2021, the cancer prevention and treatment center of Sun Yat sen University led two phase
III, double-blind, randomized controlled clinical studies of immunotherapy combined with
gemcitabine and cisplatin (GP) chemotherapy for advanced first-line nasopharyngeal carcinoma:
captain-1st study and jupiter-02 study. Captain-1st study [45] confirmed that in the
first-line treatment of locally recurrent or metastatic nasopharyngeal carcinoma,
carrilizumab combined with GP chemotherapy was used for the first-line treatment of R / M
NPC, with a median PFS of 10.8 months, an orr of 88.1%, a median duration of remission (DOR)
of 9.9 months, and good safety. The jupiter-02 study [46] confirmed that in the first-line
treatment of locally recurrent or metastatic nasopharyngeal carcinoma, the first-line
treatment of R / M NPC with treprizumab combined with GP chemotherapy had a median PFS of
11.7 months, HR of 0.52, and median dor of 10.0 months. The risk of death was reduced by 40%,
and the safety was good. These two studies confirmed that although the adverse reactions of
chemotherapy combined with PD-1 mAb were different compared with the placebo group, the
overall safety was controllable.
Compared with PD-1 inhibitor immunomonotherapy, PD-1 monoclonal antibody combined
chemotherapy can bring longer survival benefits to patients in the treatment of recurrent /
metastatic nasopharyngeal carcinoma, obtain better treatment effect and controllable safety.
However, some patients still have poor treatment effect, with an effective rate of about 50%,
which poses a severe challenge to the era of immunotherapy for recurrent / metastatic
nasopharyngeal carcinoma.
At present, a large number of basic studies have confirmed that PD-1 inhibitors have
synergistic effects with radiotherapy. Radiotherapy can stimulate the immune response,
promote the death of immunogenic cells and release tumor associated antigen (TAA), and
enhance the homing of immune cells to tumors, thus transforming immunologically "cold" tumors
into "hot" tumors. In addition, radiotherapy induces an increase in PD-L1 expression on tumor
cells, making them more susceptible to continuous effects of PD-1 / PD-L1 inhibitors, thus
promoting longer survival time and higher response rate. In addition, radiotherapy may cause
distant effect, shrink the target tumor outside the radiation field area, and may also
increase the aggregation of T cells in the tumor microenvironment, promote cytokine secretion
and antigen presentation.
Recently, Professor Chen Mingyuan from the cancer prevention and treatment center of Sun Yat
sen University led an open, single arm, phase II clinical study to explore the efficacy and
safety of treprizumab combined with intensity modulated conformal radiotherapy (IMRT) in the
treatment of recurrent nasopharyngeal carcinoma (rnpc) [63]. In this study, 25 patients with
unresectable rnpc were included. All patients received treprizumab combined with IMRT, with a
median IMRT dose of 60.21 Gy. The results showed that after 3 months of radiotherapy, the
objective response rate (ORR) was 79.2% and the disease control rate was 95.8% in 24
evaluable patients. The median PFS was 18.67 months, the 12-month PFS rate was 91.8%, and the
median OS was not reached. In terms of safety, the most common adverse events (AES) were all
grade 1-2, and the safety was manageable. It has been proved that treprizumab combined with
IMRT showed promising antitumor activity in patients with recurrent nasopharyngeal carcinoma,
achieved good remission rate and PFS outcome, and was well tolerated.
At present, PD-1 inhibitor immunomonotherapy or combined chemotherapy has been widely used in
patients with recurrent / metastatic nasopharyngeal carcinoma, and it is also the first-line
treatment for R / M NPC recommended by international and domestic guidelines. However, few
studies have focused on the simultaneous combination of PD-1 inhibitors and
chemoradiotherapy. More trials are needed to explore the possibility of combining PD-1
inhibitors with chemoradiotherapy, which may be a new treatment strategy for these patients.
